Paget's disease of the breast differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 24: Line 24:
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases
! rowspan="5" |Begnin
! rowspan="5" |Benign or Malignant
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired
! colspan="8" |Clinical manifestations
! colspan="8" |Clinical manifestations
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="2" rowspan="2" |Para-clinical findings
| rowspan="5" |Gold Standard
| colspan="2" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Associated factors'''
| colspan="2" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Associated factors'''
|-
|-
! colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
! colspan="2" rowspan="2" |Physical examination
|-
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
!Lab Findings
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
|-
|-
! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
! colspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Appearance
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Itching
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Itching
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Mastalgia
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Eosinophils
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum IgE  
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum IgE  
|-
|-
Line 50: Line 47:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Rash
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Involved areas
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Involved areas
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pustule
!Nipple
DIscharge
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Erythema
|-
|-
! rowspan="18" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin disorders
! rowspan="22" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin disorders
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Atopic dermatitis]]
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Atopic dermatitis]]
|
|Benign
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Epidermal barrier dysfunction
* Epidermal barrier dysfunction
* [[Immune]] dysregulation
* [[Immune]] dysregulation
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 68: Line 65:
* [[Adolescent|Adolescents]] -flexural areas and buttock-thigh creases
* [[Adolescent|Adolescents]] -flexural areas and buttock-thigh creases
* Adults - facial involvement and skin flexures  
* Adults - facial involvement and skin flexures  
|
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 84: Line 81:
* White dermographism
* White dermographism
* Perifollicular accentuation
* Perifollicular accentuation
| align="center" style="background:#F5F5F5;" | Nl to ↑
([[Eosinophilia|Eosinophilia)]]
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 95: Line 89:
* Psoriasiform [[hyperplasia]]
* Psoriasiform [[hyperplasia]]
* Dyskeratosis
* Dyskeratosis
|
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
*  
*  
Line 102: Line 97:
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Allergic contact dermatitis]]<ref name="pmid19447733">{{cite journal |vauthors=Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF |title=Allergic and irritant contact dermatitis |journal=Eur J Dermatol |volume=19 |issue=4 |pages=325–32 |date=2009 |pmid=19447733 |doi=10.1684/ejd.2009.0686 |url=}}</ref>
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Allergic contact dermatitis]]<ref name="pmid19447733">{{cite journal |vauthors=Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF |title=Allergic and irritant contact dermatitis |journal=Eur J Dermatol |volume=19 |issue=4 |pages=325–32 |date=2009 |pmid=19447733 |doi=10.1684/ejd.2009.0686 |url=}}</ref>
|
|Benign
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Delayed-type [[hypersensitivity]] response
* Delayed-type [[hypersensitivity]] response
* Skin [[inflammation]] mediated by [[Haptens|hapten]]-specific T cells
* Skin [[inflammation]] mediated by [[Haptens|hapten]]-specific T cells
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |May be multiple after 1-2 days of exposure
| align="center" style="background:#F5F5F5;" |May be multiple after 1-2 days of exposure
| align="center" style="background:#F5F5F5;" | Erythematous well-demarcated [[papules]]
| align="center" style="background:#F5F5F5;" | Erythematous well-demarcated [[papules]]
| align="center" style="background:#F5F5F5;" | Surrounding the area in contact with the offending agent  
| align="center" style="background:#F5F5F5;" | Surrounding the area in contact with the offending agent  
|
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 119: Line 112:
* Localized [[swelling]]
* Localized [[swelling]]
* [[Lichenification|Lichenified]] [[Itch|pruritic]] [[plaques]]
* [[Lichenification|Lichenified]] [[Itch|pruritic]] [[plaques]]
| align="center" style="background:#F5F5F5;" |Nl to ↑
([[Eosinophilia]])
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 126: Line 117:
* [[Exocytosis]] of [[eosinophils]] and [[lymphocytes]]  
* [[Exocytosis]] of [[eosinophils]] and [[lymphocytes]]  
* Chronic - [[Hyperkeratosis]] and parakeratosis
* Chronic - [[Hyperkeratosis]] and parakeratosis
|
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Contact with [[allergens]] in the past 1-2 days
* Contact with [[allergens]] in the past 1-2 days
Line 131: Line 123:
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Irritant contact dermatitis]]<ref name="pmid30293200">{{cite journal |vauthors=Bains SN, Nash P, Fonacier L |title=Irritant Contact Dermatitis |journal=Clin Rev Allergy Immunol |volume= |issue= |pages= |date=October 2018 |pmid=30293200 |doi=10.1007/s12016-018-8713-0 |url=}}</ref>
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Irritant contact dermatitis]]<ref name="pmid30293200">{{cite journal |vauthors=Bains SN, Nash P, Fonacier L |title=Irritant Contact Dermatitis |journal=Clin Rev Allergy Immunol |volume= |issue= |pages= |date=October 2018 |pmid=30293200 |doi=10.1007/s12016-018-8713-0 |url=}}</ref>
|
|Benign
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Activation of the [[innate immune system]] by the pro-[[inflammatory]] properties of chemicals
* Activation of the [[innate immune system]] by the pro-[[inflammatory]] properties of chemicals
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |Usually single immediately after the exposure
| align="center" style="background:#F5F5F5;" |Usually single immediately after the exposure
| align="center" style="background:#F5F5F5;" | Well-demarcated red patch with a glazed surface
| align="center" style="background:#F5F5F5;" | Well-demarcated red patch with a glazed surface
| align="center" style="background:#F5F5F5;" | Any area in contact with the irritant
| align="center" style="background:#F5F5F5;" | Any area in contact with the irritant
|
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 147: Line 137:
* Dryness
* Dryness
* Thicker skin
* Thicker skin
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 153: Line 142:
* Intraepidermal [[vesicles]] or bullae
* Intraepidermal [[vesicles]] or bullae
* [[Necrosis]] of [[keratinocytes]]
* [[Necrosis]] of [[keratinocytes]]
|
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Cumulative exposure to [[irritants]]
* Cumulative exposure to [[irritants]]
Line 158: Line 148:
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Psoriasis]]
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Psoriasis]]
|
|Benign
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Keratinocyte]] hyperproliferation
* [[Keratinocyte]] hyperproliferation
* Dysregulation of the [[immune system]]
* Dysregulation of the [[immune system]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Well-circumscribed, pink [[papules]] and symmetrically distributed cutaneous [[plaques]] with silvery scales
| align="center" style="background:#F5F5F5;" | Well-circumscribed, pink [[papules]] and symmetrically distributed cutaneous [[plaques]] with silvery scales
Line 171: Line 159:
* Gluteal cleft
* Gluteal cleft
* Extensor surface of elbows and knees
* Extensor surface of elbows and knees
|
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | _
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Auspitz's sign]]  (pinpoint bleeding)
* [[Auspitz's sign]]  (pinpoint bleeding)
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 183: Line 170:
* Parakeratosis
* Parakeratosis
* [[Neutrophils]] microabscesses (Munro microabscesses)
* [[Neutrophils]] microabscesses (Munro microabscesses)
|
| colspan="2" align="center" style="background:#F5F5F5;" |Risk factors include
| colspan="2" align="center" style="background:#F5F5F5;" |Risk factors include
* [[Smoking]]
* [[Smoking]]
Line 192: Line 180:
|-
|-
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Eczema|Chronic eczema]]
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Eczema|Chronic eczema]]
|
|Benign
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
*  
*  
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Scalp, face, trunk, postauricular, diaper area and axilla
| align="center" style="background:#F5F5F5;" | Scalp, face, trunk, postauricular, diaper area and axilla
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
|
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
**  
**  
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 211: Line 196:
* Psoriasiform [[hyperplasia]]
* Psoriasiform [[hyperplasia]]
* [[Neutrophils]] at the margins
* [[Neutrophils]] at the margins
| colspan="2" align="center" style="background:#F5F5F5;" |Risk factors include
| colspan="3" align="center" style="background:#F5F5F5;" |Risk factors include
* [[Stress]]
* [[Stress]]


Line 221: Line 206:
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
![[Bowen’s disease]]
!
!
!
!
Line 236: Line 235:
!
!
|-
|-
![[Bowen’s disease]]
![[Basal cell carcinoma|Superficial basal cell carcinoma]]
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
|-
![[Basal cell carcinoma|Pagetoid basal cell carcinoma]]
!
!
!
!
Line 254: Line 267:
!
!
|-
|-
![[Basal cell carcinoma|Superficial basal cell carcinoma]]
![[Intraductal papilloma|Benign intraductal papilloma]]
!
!
!
!
!
!
!
!
!
!
!
!
!
Line 260: Line 282:
!
!
!
!
|-
!Pagetoid dyskeratosis
!
!
!
!
Line 271: Line 295:
!
!
!
!
|-
![[Basal cell carcinoma|Pagetoid basal cell carcinoma]]
!
!
!
!
!
!
|-
![[Duct ectasia of breast|Lactiferous duct ectasia]]
!Benign
!
!
* Common among [[perimenopausal]]<nowiki/>women
* Usually resolve spontaneously
!
!
!
!
Line 290: Line 317:
!
!
|-
|-
![[Intraductal papilloma|Benign intraductal papilloma]]
!Nipple duct adenoma
!
!
!
!
!
!
Line 303: Line 332:
!
!
!
!
|-
!Benign Toker cell  hyperplasia
!
!
!
!
!
!
!
!
|-
!Pagetoid dyskeratosis
!
!
!
!
Line 319: Line 348:
!
!
!
!
|-
![[Mastitis]]
!Benign
!
!
!
!
Line 325: Line 357:
!
!
!
!
|-
![[Duct ectasia of breast|Lactiferous duct ectasia]]
!
!
!+
!
!
!
!
Line 333: Line 364:
!
!
!
!
|-
![[Mondors disease]]
!
!
!
!
Line 343: Line 376:
!
!
!
!
|-
!Nipple duct adenoma
!
!
!
!
!
!
!
!
|-
![[Breast abscess]]
!Benign
!
!
!
!
Line 356: Line 390:
!
!
!
!
!+
!
!
!
!

Revision as of 22:00, 20 February 2019

Paget's disease of the breast Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Paget's disease of the breast from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Biopsy

Ultrasonography

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Paget's disease of the breast differential diagnosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Paget's disease of the breast differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Paget's disease of the breast differential diagnosis

CDC on Paget's disease of the breast differential diagnosis

Paget's disease of the breast differential diagnosis in the news

Blogs on Paget's disease of the breast differential diagnosis

Directions to Hospitals Treating Paget's disease of the breast

Risk calculators and risk factors for Paget's disease of the breast differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Suveenkrishna Pothuru, M.B,B.S. [2]

Overview

Paget's disease of the breast must be differentiated from atopic dermatitis, eczema, psoriasis, malignant melanoma, Bowen's disease, basal cell carcinoma, and pagetoid dyskeratosis.[1][2]

Differential Diagnosis

Paget’s disease of the breast must be differentiated from other benign and malignant processes of nipple-areola complex such as:[1][2]

Category Diseases Benign or Malignant Etiology Clinical manifestations Para-clinical findings Gold Standard Associated factors
Symptoms Physical examination
Lab Findings Histopathology
Appearance Itching Mastalgia Other Serum IgE
Single/

Multiple

Rash Involved areas Nipple

DIscharge

Erythema
Skin disorders Atopic dermatitis Benign
  • Epidermal barrier dysfunction
  • Immune dysregulation
Multiple
  • Young children -Scalp, cheeks amd extensor surface
  • Adolescents -flexural areas and buttock-thigh creases
  • Adults - facial involvement and skin flexures
+
  • Infra-auricular and retro-auricular fissuring
  • Nipple eczema
  • White dermographism
  • Perifollicular accentuation
  • Epidermal psoriasiform hyperplasia
  • Marked intercellular edema with spongiotic vesiculation
Allergic contact dermatitis[3] Benign May be multiple after 1-2 days of exposure Erythematous well-demarcated papules Surrounding the area in contact with the offending agent + + Nl
Irritant contact dermatitis[4] Benign Usually single immediately after the exposure Well-demarcated red patch with a glazed surface Any area in contact with the irritant + + Nl
  • Cumulative exposure to irritants
  • Negative hypersensitivity tests
Psoriasis Benign Multiple Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales
  • Scalp
  • Trunk
  • Gluteal cleft
  • Extensor surface of elbows and knees
+ + + Nl Risk factors include
Chronic eczema Benign
Scalp, face, trunk, postauricular, diaper area and axilla + +
Nl Risk factors include

Generalized seborrheic erythroderma in immunodeficient patients

Malignant melanoma
Bowen’s disease
Superficial basal cell carcinoma
Pagetoid basal cell carcinoma
Benign intraductal papilloma
Pagetoid dyskeratosis
Lactiferous duct ectasia Benign
Nipple duct adenoma
Benign Toker cell hyperplasia
Mastitis Benign +
Mondors disease
Breast abscess Benign +

References

  1. 1.0 1.1 Gaspari, Eleonora; Ricci, Aurora; Liberto, Valeria; Scarano, Angela Lia; Fornari, Maria; Simonetti, Giovanni (2013). "An Unusual Case of Mammary Paget's Disease Diagnosed Using Dynamic Contrast-Enhanced MRI". Case Reports in Radiology. 2013: 1–5. doi:10.1155/2013/206235. ISSN 2090-6862.
  2. 2.0 2.1 Lopes Filho, Lauro Lourival; Lopes, Ione Maria Ribeiro Soares; Lopes, Lauro Rodolpho Soares; Enokihara, Milvia M. S. S.; Michalany, Alexandre Osores; Matsunaga, Nobuo (2015). "Mammary and extramammary Paget's disease". Anais Brasileiros de Dermatologia. 90 (2): 225–231. doi:10.1590/abd1806-4841.20153189. ISSN 1806-4841.
  3. Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF (2009). "Allergic and irritant contact dermatitis". Eur J Dermatol. 19 (4): 325–32. doi:10.1684/ejd.2009.0686. PMID 19447733.
  4. Bains SN, Nash P, Fonacier L (October 2018). "Irritant Contact Dermatitis". Clin Rev Allergy Immunol. doi:10.1007/s12016-018-8713-0. PMID 30293200.